Skip to main content

Table 6 Discounted base case model outcomes

From: Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma

  VR-CAP R-CHOP Differencea
Deterministic results
 QALYs 4.10 3.29 0.81
  Progression-free survival from first-line treatment 2.70 1.54 1.16
  Progressed from first-line treatment 0.14 0.10 0.03
  Progression-free survival from second-line treatment 0.12 0.15 −0.03
  Progressed from second-line treatment 1.15 1.50 −0.35
 Costs £45,842 £29,630 £16,212
  First line therapy medication costs £22,606 £8,041 £14,566
  Administration of first line therapy £5,817 £1,564 £4,253
  Adverse events, transfusions & concomitant medication £1,472 £1,105 £367
  Disease management costs £4,191 £4,676 −£486
  Second line treatment (medication and administration) £7,152 £9,423 −£2,271
  Terminal care £4,605 £4,821 −£217
 Deterministic ICER (£/QALY gained)    £20,043
Probabilistic results    
 QALYs 4.09 3.28 0.81
 Costs £45,482 £29,285 £16,196
Probabilistic ICER (£/QALY gained)    £19,889
  1. Abbreviations: ICER incremental cost-effectiveness ratio, QALY quality-adjusted life year, R-CHOP rituximab with cyclophosphamide, doxorubicin, vincristine and prednisolone, VR-CAP bortezomib with rituximab, cyclophosphamide, doxorubicin and prednisolone
  2. aSome differences due to rounding. First line therapy costs: medication costs of first line treatment; Administration costs: costs of administration of first-line therapies; Adverse events and concomitant medication costs: costs associated with adverse events (treatment of adverse events, concomitant medication and transfusions); Medical resource use; all costs for disease management, such as follow up visits and tests; Second line treatment costs; costs for medication and administration of the subsequent line of treatment; Terminal care costs: costs for end-of-life care
  3. Total costs and QALYs, as well as the ICERs are presented in bold text